Segment Information

6 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Segment Information

Segment Information

The Company operates as two reportable segments:

• The Consumer Operations segment, which reflects the total revenue and costs and expenses related to HOTSHOT and the Company's consumer operations.

• The Drug Development segment, which reflects the costs and expenses related to the Company's efforts to develop innovative and proprietary drug products to treat muscle cramps and spasticity associated with severe neurological conditions.

The Company discloses information about its reportable segments based on the way that the Company's Chief Operating Decision Maker, who the Company has identified as the Chief Executive Officer, and management, organize segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its reportable segments based on revenue and operating income or loss. The accounting policies of the segments are the same as those described herein as well as those described in Note 2 to the audited consolidated financial statements in the 2016 Form 10-K. Corporate and unallocated amounts that do not relate to a reportable segment have been allocated to "Corporate". No asset information has been provided for the Company's reportable segments as management does not measure or allocate such assets on a reportable segment basis.

Information for the Company's reportable segments for the three months ended June 30, 2017 and 2016 are as follows:

Three months Ended June 30, 2017	Consumer Operations		Drug Development	Corporate	Consolidated
Total revenue	$	335,523	—	—	$	335,523
Interest income, net	$	—	—	72,342	$	72,342
Loss from operations	$	2,760,496	3,960,335	2,156,134	$	8,876,965

Three months Ended June 30, 2016	Consumer Operations		Drug Development	Corporate	Consolidated
Total revenue	$	112,685	—	—	$	112,685
Interest income, net	$	—	—	107,818	$	107,818
Loss from operations	$	2,841,848	5,907,774	2,721,329	$	11,470,951

Information for the Company's reportable segments for the six months ended June 30, 2017 and 2016 are as follows:

Six Months Ended June 30, 2017	Consumer Operations		Drug Development	Corporate	Consolidated
Total revenue	$	578,070	—	—	$	578,070
Interest income, net	$	—	—	150,196	$	150,196
Loss from operations	$	4,748,306	7,788,616	4,686,292	$	17,223,214

Six Months Ended June 30, 2016	Consumer Operations		Drug Development	Corporate	Consolidated
Total revenue	$	112,685	—	—	$	112,685
Interest income, net	$	—	—	211,151	$	211,151
Loss from operations	$	5,771,202	9,966,817	5,428,726	$	21,166,745